Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharmaust Limited ( (AU:NUZ) ) has issued an update.
Neurizon Therapeutics Limited has announced the cessation of Dr Michael Thurn as a director effective 8 May 2026, detailing his remaining interests in performance rights, unlisted options and fully paid ordinary shares. The disclosure clarifies Dr Thurn’s equity holdings, including those held via a family account, providing transparency for investors on changes to board composition and associated director-linked securities.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.28 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a biotechnology company focused on developing therapeutic treatments, operating within the pharmaceutical and life sciences sector. The company’s securities structure includes performance rights, unlisted options and fully paid ordinary shares held by directors and related parties, reflecting equity-based incentives typical of early-stage drug development firms.
Average Trading Volume: 509,966
Technical Sentiment Signal: Sell
Current Market Cap: A$56.72M
For detailed information about NUZ stock, go to TipRanks’ Stock Analysis page.